Median Technologies Secures Major €8.4 Million iCRO Project

Median Technologies has announced a significant achievement with the signing of a large-scale iCRO project worth €8.4 million. The project, granted by a major European pharmaceutical company, will involve imaging services for a global Phase III clinical trial focused on a rare brain cancer. This trial spans over 150 investigator sites worldwide, promising to enhance Median's order backlog and revenue predictability.

This project underscores Median’s strength in handling extensive oncology programs, cementing its role as a key imaging partner for intricate international clinical trials. The initiative also supports the Company's strategic focus on collaborating with leading pharmaceutical firms.

The trial will require extensive imaging reviews and advanced 3D analysis, further emphasizing Median's capability in delivering comprehensive imaging solutions and operational efficiency on a global scale.